JP2016520135A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520135A5 JP2016520135A5 JP2016517607A JP2016517607A JP2016520135A5 JP 2016520135 A5 JP2016520135 A5 JP 2016520135A5 JP 2016517607 A JP2016517607 A JP 2016517607A JP 2016517607 A JP2016517607 A JP 2016517607A JP 2016520135 A5 JP2016520135 A5 JP 2016520135A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- pharmaceutical dosage
- form according
- water
- coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002552 dosage form Substances 0.000 claims 16
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 4
- 239000011248 coating agent Substances 0.000 claims 4
- 238000000576 coating method Methods 0.000 claims 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 3
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 229920003169 water-soluble polymer Polymers 0.000 claims 3
- 239000005541 ACE inhibitor Substances 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- -1 focinopril Chemical compound 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 229960003401 ramipril Drugs 0.000 claims 2
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims 2
- 230000036454 renin-angiotensin system Effects 0.000 claims 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims 2
- VWWMGPCUZVOLLK-UHFFFAOYSA-N 2-[4-[(2-cyclopropyl-7-methylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]benzoic acid Chemical compound C1CC1C1=NC=2C(C)=CC=NC=2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O VWWMGPCUZVOLLK-UHFFFAOYSA-N 0.000 claims 1
- FSJCYXPMWQPVOS-UHFFFAOYSA-N 2-ethyl-4-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methoxy]quinoline Chemical compound C=12C=CC=CC2=NC(CC)=CC=1OCC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 FSJCYXPMWQPVOS-UHFFFAOYSA-N 0.000 claims 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 239000005485 Azilsartan Substances 0.000 claims 1
- 239000002083 C09CA01 - Losartan Substances 0.000 claims 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims 1
- 239000002081 C09CA05 - Tasosartan Substances 0.000 claims 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 108010061435 Enalapril Proteins 0.000 claims 1
- 108010007859 Lisinopril Proteins 0.000 claims 1
- 239000005480 Olmesartan Substances 0.000 claims 1
- XRKXJJYSKUIIEN-LLVKDONJSA-N Pivopril Chemical compound CC(C)(C)C(=O)SC[C@@H](C)C(=O)N(CC(O)=O)C1CCCC1 XRKXJJYSKUIIEN-LLVKDONJSA-N 0.000 claims 1
- 239000005478 Saprisartan Substances 0.000 claims 1
- DUEWVPTZCSAMNB-UHFFFAOYSA-N Saprisartan Chemical compound NC(=O)C=1N(CC=2C=C3C(Br)=C(OC3=CC=2)C=2C(=CC=CC=2)NS(=O)(=O)C(F)(F)F)C(CC)=NC=1C1CC1 DUEWVPTZCSAMNB-UHFFFAOYSA-N 0.000 claims 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 claims 1
- 239000008351 acetate buffer Substances 0.000 claims 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 claims 1
- 229960002731 azilsartan Drugs 0.000 claims 1
- 229960000932 candesartan Drugs 0.000 claims 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960000830 captopril Drugs 0.000 claims 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 1
- 229960005025 cilazapril Drugs 0.000 claims 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 claims 1
- 239000008199 coating composition Substances 0.000 claims 1
- 229960005227 delapril Drugs 0.000 claims 1
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 claims 1
- 229960000873 enalapril Drugs 0.000 claims 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 1
- 229960004563 eprosartan Drugs 0.000 claims 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims 1
- YONOBYIBNBCDSJ-UHFFFAOYSA-N forasartan Chemical compound N1=C(CCCC)N=C(CCCC)N1CC1=CC=C(C=2C(=CC=CC=2)C2=NNN=N2)N=C1 YONOBYIBNBCDSJ-UHFFFAOYSA-N 0.000 claims 1
- 229950003641 forasartan Drugs 0.000 claims 1
- 229950009810 indolapril Drugs 0.000 claims 1
- 229960002198 irbesartan Drugs 0.000 claims 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 1
- 229960002394 lisinopril Drugs 0.000 claims 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims 1
- 229960004773 losartan Drugs 0.000 claims 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims 1
- 229960005117 olmesartan Drugs 0.000 claims 1
- 229960002582 perindopril Drugs 0.000 claims 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims 1
- 229950008688 pivopril Drugs 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229960001455 quinapril Drugs 0.000 claims 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims 1
- BSHDUMDXSRLRBI-JOYOIKCWSA-N rentiapril Chemical compound SCCC(=O)N1[C@H](C(=O)O)CS[C@@H]1C1=CC=CC=C1O BSHDUMDXSRLRBI-JOYOIKCWSA-N 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 229950006241 saprisartan Drugs 0.000 claims 1
- 229960002909 spirapril Drugs 0.000 claims 1
- 108700035424 spirapril Proteins 0.000 claims 1
- HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 claims 1
- 229960000651 tasosartan Drugs 0.000 claims 1
- ADXGNEYLLLSOAR-UHFFFAOYSA-N tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 claims 1
- 229960005187 telmisartan Drugs 0.000 claims 1
- 229960004699 valsartan Drugs 0.000 claims 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 229920003176 water-insoluble polymer Polymers 0.000 claims 1
- 229960002769 zofenopril Drugs 0.000 claims 1
- IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13170909.9A EP2810644A1 (en) | 2013-06-06 | 2013-06-06 | Oral formulation for the treatment of cardiovascular diseases |
| EP13170909.9 | 2013-06-06 | ||
| PCT/EP2014/061735 WO2014195421A1 (en) | 2013-06-06 | 2014-06-05 | Oral formulation for the treatment of cardiovascular diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016520135A JP2016520135A (ja) | 2016-07-11 |
| JP2016520135A5 true JP2016520135A5 (https=) | 2016-11-10 |
| JP6151854B2 JP6151854B2 (ja) | 2017-06-21 |
Family
ID=48569993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016517607A Active JP6151854B2 (ja) | 2013-06-06 | 2014-06-05 | 心血管疾患の治療用経口製剤 |
Country Status (42)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE061213T2 (hu) * | 2015-04-16 | 2023-05-28 | Novartis Ag | Ribociklib tabletta |
| CN111135149B (zh) * | 2018-11-04 | 2021-05-11 | 张家港市中医医院 | 一种瑞舒伐他汀钙片及其制备方法 |
| CN110693929A (zh) * | 2019-09-09 | 2020-01-17 | 安徽中医药大学 | 复方药物组份在治疗脑梗死恢复期中的应用 |
| HUE066396T2 (hu) | 2022-06-30 | 2024-08-28 | Ferrer Int | Orális kapszulák, amelyek atorvasztatin tablettákat tartalmaznak, amelyek megfelelõ oldódási profilt és biológiai hozzáférhetõséget mutatnak |
| CO2025012256A1 (es) | 2024-09-12 | 2026-03-16 | Laboratorios Silanes S A De C V | Composición farmacéutica que comprende rosuvastatina y ácido acetilsalicílico, proceso de preparación y usos de la misma |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| HU204253B (en) | 1982-11-22 | 1991-12-30 | Sandoz Ag | Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them |
| MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
| AU732465B2 (en) | 1996-04-17 | 2001-04-26 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
| US6235311B1 (en) * | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
| US6197959B1 (en) | 1999-04-27 | 2001-03-06 | Hoffmann-La Roche Inc. | Piperidine derivatives |
| US6376672B1 (en) | 1999-04-27 | 2002-04-23 | Hoffmann-La Roche Inc. | Naphthalenylmethoxypiperidines as renin inhibitors |
| US6448323B1 (en) | 1999-07-09 | 2002-09-10 | Bpsi Holdings, Inc. | Film coatings and film coating compositions based on polyvinyl alcohol |
| KR20030025903A (ko) | 2000-02-10 | 2003-03-29 | 비피에스아이 홀딩스, 인코포레이션. | 아크릴 장용 코팅 조성물 |
| US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
| US6576256B2 (en) * | 2001-08-28 | 2003-06-10 | The Brigham And Women's Hospital, Inc. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
| US20040115265A1 (en) * | 2002-12-11 | 2004-06-17 | Loutfy Benkerrour | Multilayered tablet containing pravastatin and aspirin and method |
| WO2004080488A2 (de) | 2003-03-10 | 2004-09-23 | Bayer Healthcare Ag | Kombinationspräparate von acetylsalicylsäure mit einem hmg-coa-reduktase |
| NZ544784A (en) * | 2003-07-28 | 2009-11-27 | Reddys Lab Inc Dr | Treatment and prevention of cardiovascular events using a beta-adrenergic receptor antagonist, a diuretic, an inhibitor of HMG CoA reductase, an inhibitor of the rennin-angiotensin system and asprin; wherein acidic and basic components are separated. |
| ES2395724T3 (es) | 2003-08-20 | 2013-02-14 | Shionogi & Co., Ltd. | Nueva composición de recubrimiento |
| AU2004293178B8 (en) | 2003-11-26 | 2009-01-08 | Novartis Ag | Organic compounds |
| EP1784193A4 (en) * | 2004-06-28 | 2009-09-23 | Smith Howard J & Ass Pty Ltd | COMPOSITION AND METHOD FOR THE TREATMENT AND PREVENTION OF ATHEROSCLEROSIS |
| WO2010127205A2 (en) * | 2009-04-30 | 2010-11-04 | Dr. Reddy's Laboratories Ltd. | Fixed dose drug combination formulations |
| JP2008532983A (ja) | 2005-03-11 | 2008-08-21 | シュペーデル・エクスペリメンタ・アーゲー | レニン阻害剤として有用な複素環置換アルカンアミド |
| US20070009591A1 (en) | 2005-07-07 | 2007-01-11 | Trivedi Jay S | ACE inhibitor formulation |
| US20070116756A1 (en) | 2005-11-23 | 2007-05-24 | Dr. Reddy's Laboratories Limited | Stable pharmaceutical compositions |
| US7427414B2 (en) | 2006-01-18 | 2008-09-23 | Astron Research Limited | Modified release oral dosage form using co-polymer of polyvinyl acetate |
| CN101176725A (zh) * | 2006-07-14 | 2008-05-14 | 兰贝克赛实验室有限公司 | 辛伐他汀和阿司匹林的稳定剂型 |
| PL2120878T3 (pl) * | 2007-02-09 | 2015-01-30 | Alphapharm Pty Ltd | Postać dawkowania zawierająca dwa czynne składniki farmaceutyczne o różnych postaciach fizycznych |
| WO2009022821A2 (en) | 2007-08-13 | 2009-02-19 | Hanall Pharmaceutical Company. Ltd | Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same |
| US20090076062A1 (en) | 2007-09-13 | 2009-03-19 | Juergen Klaus Maibaum | Organic Compounds |
| RU2477123C2 (ru) * | 2008-03-28 | 2013-03-10 | Феррер Интернасионал, С.А. | Капсула и лекарственное средство для профилактики сердечно-сосудистых заболеваний |
| CA2754134C (en) * | 2009-02-11 | 2018-09-18 | Cadila Pharmaceuticals Ltd. | Stable pharmaceutical composition for atherosclerosis |
| KR20120130078A (ko) | 2009-11-09 | 2012-11-28 | 메디비르 아베 | 신규한 1,3-옥사졸리딘 화합물 및 이의 레닌 억제제로서의 용도 |
| KR101193493B1 (ko) * | 2010-02-02 | 2012-10-22 | 한미사이언스 주식회사 | 소수성 첨가제가 함유된 분리막으로 코팅된 아스피린 및 ＨＭＧ?ＣｏＡ 환원효소 억제제를 포함하는 복합제제 |
| CN102049049A (zh) * | 2010-11-27 | 2011-05-11 | 王定豪 | 包含阿司匹林盐和他汀类药物的药物组合物 |
-
2013
- 2013-06-06 EP EP13170909.9A patent/EP2810644A1/en not_active Withdrawn
-
2014
- 2014-05-20 AR ARP140101992A patent/AR096350A1/es not_active Application Discontinuation
- 2014-06-04 TW TW103119340A patent/TWI630928B/zh active
- 2014-06-05 EA EA201600012A patent/EA028969B1/ru unknown
- 2014-06-05 MD MDA20160001A patent/MD4475C1/ro active IP Right Grant
- 2014-06-05 ES ES14728940.9T patent/ES2620078T3/es active Active
- 2014-06-05 MY MYPI2015704409A patent/MY181272A/en unknown
- 2014-06-05 AU AU2014276883A patent/AU2014276883B2/en active Active
- 2014-06-05 UA UAA201512002A patent/UA113806C2/uk unknown
- 2014-06-05 MA MA38699A patent/MA38699B1/fr unknown
- 2014-06-05 MX MX2015015753A patent/MX347801B/es active IP Right Grant
- 2014-06-05 JP JP2016517607A patent/JP6151854B2/ja active Active
- 2014-06-05 WO PCT/EP2014/061735 patent/WO2014195421A1/en not_active Ceased
- 2014-06-05 PT PT147289409T patent/PT2986281T/pt unknown
- 2014-06-05 CU CUP2015000173A patent/CU24326B1/es unknown
- 2014-06-05 DK DK14728940.9T patent/DK2986281T3/en active
- 2014-06-05 BR BR112015030350-1A patent/BR112015030350B1/pt not_active IP Right Cessation
- 2014-06-05 SI SI201430175A patent/SI2986281T1/sl unknown
- 2014-06-05 EP EP14728940.9A patent/EP2986281B1/en active Active
- 2014-06-05 AP AP2015008882A patent/AP2015008882A0/xx unknown
- 2014-06-05 SG SG11201509353QA patent/SG11201509353QA/en unknown
- 2014-06-05 KR KR1020157033956A patent/KR101839665B1/ko not_active Expired - Fee Related
- 2014-06-05 RS RS20170286A patent/RS55786B1/sr unknown
- 2014-06-05 PE PE2015002519A patent/PE20160051A1/es unknown
- 2014-06-05 GE GEAP201414027A patent/GEP201706743B/en unknown
- 2014-06-05 HU HUE14728940A patent/HUE033458T2/en unknown
- 2014-06-05 PL PL14728940T patent/PL2986281T3/pl unknown
- 2014-06-05 CA CA2912350A patent/CA2912350C/en active Active
- 2014-06-05 NZ NZ714707A patent/NZ714707A/en unknown
- 2014-06-05 TN TN2015000501A patent/TN2015000501A1/en unknown
- 2014-06-05 US US14/893,902 patent/US10617699B2/en active Active
- 2014-06-05 EP EP16204436.6A patent/EP3175849A1/en not_active Withdrawn
- 2014-06-06 CN CN202110259129.4A patent/CN113143888A/zh active Pending
- 2014-06-06 CN CN201410249657.1A patent/CN104224804A/zh active Pending
-
2015
- 2015-05-28 HK HK15105100.9A patent/HK1204562A1/xx unknown
- 2015-11-12 IL IL242569A patent/IL242569B/en active IP Right Grant
- 2015-11-16 ZA ZA2015/08452A patent/ZA201508452B/en unknown
- 2015-12-01 EC ECIEPI201550273A patent/ECSP15050273A/es unknown
- 2015-12-03 CR CR20150635A patent/CR20150635A/es unknown
- 2015-12-04 PH PH12015502706A patent/PH12015502706A1/en unknown
- 2015-12-04 NI NI201500171A patent/NI201500171A/es unknown
- 2015-12-04 CL CL2015003561A patent/CL2015003561A1/es unknown
- 2015-12-05 SA SA515370243A patent/SA515370243B1/ar unknown
- 2015-12-08 DO DO2015000296A patent/DOP2015000296A/es unknown
-
2017
- 2017-03-17 CY CY20171100340T patent/CY1118766T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520135A5 (https=) | ||
| RU2012122886A (ru) | Капсулы активных фармацевтических ингредиентов и сложных эфиров полиненасыщенной жирной кислоты для лечения сердечно-сосудистых заболеваний | |
| JP2018507244A5 (https=) | ||
| JP2013506684A5 (https=) | ||
| RU2014111474A (ru) | Способы лечения сердечно-сосудистых нарушений | |
| FI3182975T3 (fi) | Rukaparibin suuren annosvahvuuden tabletteja | |
| RU2015110825A (ru) | Устойчивая к действию желудочного сока фармацевтическая или нутрицевтическая композиция со стойкостью к влиянию этанола | |
| WO2012091153A3 (en) | Orally disintegrating tablet | |
| JP2016053057A5 (https=) | ||
| RU2015110824A (ru) | Фармацевтическая или нутрицевтическая композиция с замедленным высвобождением и стойкостью к воздействию этанола | |
| NZ609533A (en) | Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats | |
| FI4076652T3 (fi) | Farmaseuttisesti hyväksyttävä atrasentanin suola käytettäväksi iga-nefropatiaan hoitomenetelmässä | |
| RU2015110979A (ru) | Комбинации ингибиторов sglt 2 и антигипертензивных лекарственных средств | |
| AR096350A1 (es) | Composición farmacéutica para administración por vía oral para su uso para la prevención y/o el tratamiento de una enfermedad cardiovascular | |
| US20160193155A1 (en) | Pulsatile-release dosage form | |
| CN106163518B (zh) | 包含血管紧张素-Ⅱ受体阻断剂和HMG-CoA还原酶抑制剂的药物组合制剂 | |
| JP2009510139A (ja) | 組合せ | |
| CN107072977A (zh) | Nep抑制剂药物组合及其应用 | |
| JP2010031006A5 (https=) | ||
| OA17601A (en) | Oral formulation for the treatment of cardiovascular diseases. |